Infliximab in a Child With Relapsing Tuberculous Meningoencephalitis: A Case Report and Literature Review
Abstract
A 5-year-old child with tuberculous meningoencephalitis developed severe drug-induced hepatitis after conventional antitubercular therapy. Consequently, standard treatment was discontinued, and second-line drugs were administered in combination with high-dose corticosteroids. However, the disease continued to progress significantly. The introduction of infliximab resulted in substantial clinical and radiologic improvement, highlighting its potential role in managing refractory cases of central nervous system tuberculosis.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.